Imigran (Sumatriptan Succinate)

Sumatriptan, the active ingredient in Imigran, selectively stimulates serotonin 5‑HT1B and 5‑HT1D receptors on cranial blood vessels and trigeminal nerve fibers. This action causes vasoconstriction of dilated intracranial vessels and blocks the release of pain‑triggering neuropeptides, thereby interrupting migraine pain pathways.

The dose of Imigran is determined by the prescribing clinician based on individual patient needs, clinical guidelines, and the severity of the migraine attack. Healthcare professionals select the appropriate amount and frequency in accordance with approved prescribing information.

Safety data for Imigran in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision should be made in consultation with a qualified healthcare provider.

To order Imigran, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling if required), and necessary import documentation.

Imigran belongs to the triptan class, which provides rapid, targeted relief for migraine attacks by acting on serotonin receptors. Compared with non‑specific analgesics, triptans like Imigran address the underlying vascular and neurogenic mechanisms of migraine, often achieving faster and more complete symptom resolution.

Imigran should be stored at room temperature, preferably below 25 °C, in its original packaging. Protect the product from moisture and direct sunlight. Do not freeze the injection solution, and keep it out of reach of children.

Imigran is administered as a subcutaneous injection, typically into the outer thigh or abdomen. The injection is performed by a qualified healthcare professional or by the patient after proper training, using a sterile, single‑use device provided with the product.

Serious risks include coronary vasospasm, myocardial infarction, serotonin syndrome (especially when combined with other serotonergic drugs), severe hypertension, and anaphylactic reactions. Patients should seek immediate medical attention if they experience chest pain, severe shortness of breath, or signs of an allergic reaction.

Imigran is contraindicated in individuals with known coronary artery disease, uncontrolled hypertension, a history of myocardial infarction, severe peripheral vascular disease, or those who have previously experienced an allergic reaction to sumatriptan or any component of the formulation. It is also not recommended for children and adolescents under 18 years of age.